Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
about
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activityHow antibiotics kill bacteria: from targets to networksComparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coliContribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolatesFluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinContribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics.Suppression of reactive-oxygen-species accumulation accounts for paradoxical bacterial survival at high quinolone concentration.In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.
P2860
Q28486793-3CDFAF59-0B4A-4667-86E1-EAA795BA2BABQ33958766-C28E57EC-F99B-43C6-A516-93E77637EDD5Q34077142-0B5EB45D-0C85-442B-9784-69533ADBF970Q34538298-7A6D299A-D374-4181-8A20-566533D281E3Q36825816-5AB23CC0-C63E-423F-A902-134ECF601571Q39651272-6AB91B30-71F6-4261-A2F1-985545D8C53AQ39731893-F7CD2024-8AD4-45BA-8AD8-FEE14B46F463Q39792565-6108DABC-822B-4289-B52F-ECA8E5218755Q40469459-68C07FBF-DE19-4F71-A81D-388B604B192FQ41975822-79816633-EA33-43D1-BF04-5FB6B11B73CAQ42078632-009CC49D-F60B-4CA5-9CAA-B18EDB3B4792Q42784827-8E897F57-2055-4C5B-A43E-C31ACCD2C91CQ43251107-279BD9F4-8819-4175-8B26-81B7880D4C73Q43803237-72CA5716-272A-45F1-A0D1-3A32888E3728Q46243490-619060CA-6525-4ED1-B506-24F97AB8B671Q46514177-5AF3D97F-0FC2-456A-8DC7-385768AAD4F6Q54297668-CDEBD5C5-4C3E-4474-96D1-09A368A3CBC1Q55252138-59C0C82C-CDDF-442A-BC3F-ECBF509CF995
P2860
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@en
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@nl
type
label
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@en
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@nl
prefLabel
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@en
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@nl
P2093
P2860
P1476
Enhancement of fluoroquinolone ...... tant of Staphylococcus aureus.
@en
P2093
A Drlica-Wagner
J Domagala
P2860
P304
P356
10.1128/AAC.45.10.2703-2709.2001
P407
P577
2001-10-01T00:00:00Z